Have you been updated on Type II Diabetes research?
As of May 2, 2011, the U. S Food and Drug Administration (FDA) approved the use of Linagliptin tablets as a significant regulator of blood sugar levels in adults with Type II Diabetes. Although Linagliptin has been approved in the United States thus far, the drug is under investigation in Canada. It has reached phase III clinical trials across Canada including here at the Canadian Center for Clinical Trials (CCCT).
Type II diabetes is the most prevalent form of diabetes in North America, affecting nearly 90%-95% of all combined diabetes sufferers. This form of Diabetes is characterized by impaired blood sugar control due to the body’s inability to respond to insulin. If left untreated, it can lead to complications such as heart disease, kidney and nerve damage, as well as blindness
The good news is that the dedication and persistence of doctors and researchers has allowed for advancement in the treatment options available to patients. Various prescription medications and clinical trials offer patients today different strategies in the fight against type 2 diabetes with high success rates. Here at the Canadian Center for Clinical Trials, investigation of Linagliptin is ongoing for Type II diabetes patients.
For more information or to see if you are eligible for this trial, please visit:
Or contact us via:
Telephone: (289) 597-0106
For the official press release from Saffron-Networking, visit: